论文部分内容阅读
2006年6月,美国临床肿瘤学第42届年会会后会(post-ASCO)在上海举行。300多名国内肿瘤界的医务人员参加了这次会议,聆听由中外肿瘤学专家带来的A S C O最新研究数据,以及礼来公司在肿瘤领域特别是药物基因组学研究方面的最新进展。药物基因组学技术是目前肿瘤药物研发中新兴的一
In June 2006, the 42nd annual meeting of the American Society of Clinical Oncology (post-ASCO) was held in Shanghai. More than 300 medical staff from the domestic oncology community attended the conference to hear the latest AS C O research data brought by Chinese and foreign oncologists and the latest progress of Eli Lilly’s research in the field of oncology, especially pharmacogenomics. Pharmacogenomics technology is currently one of the emerging cancer drug development